42753-67-3

Basic information

• Product Name: CHEMPACIFIC 38169
• Synonyms: CHEMPACIFIC 38169;3-ETHYL-PYRIDIN-2-YLAMINE;2-AMINO-3-ETHYL-PYRIDINE;3-ETHYLPYRIDIN-2-AMINE;2-Pyridinamine, 3-ethyl-;3-Ethyl-2-pyridinaMine;EOS-61816
• CAS NO: 42753-67-3
• Molecular Formula: C₇H₁₀N₂
• Molecular Weight: 122.17
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 42753-67-3.mol

Chemical Properties

• Boiling Point: 236℃
• Flash Point: 119℃
• Appearance: /
• Density: 1.037
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.19±0.36(Predicted)
• CAS DataBase Reference: CHEMPACIFIC 38169(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMPACIFIC 38169(42753-67-3)
• EPA Substance Registry System: CHEMPACIFIC 38169(42753-67-3)

Safety Data

• Hazardous Substances Data: 42753-67-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CHEMPACIFIC 38169 is used as a key intermediate in the synthesis of glutaramides, which are potential inhibitors of neutral endopeptidase. Neutral endopeptidase is an enzyme that plays a role in regulating blood pressure and is a target for the development of antihypertensive drugs. By inhibiting this enzyme, glutaramides can help in the management of hypertension and other related conditions.

InChI:InChI=1S/C7H10N2/c1-2-6-4-3-5-9-7(6)8/h3-5H,2H2,1H3,(H2,8,9)

Upstream product

• 536-78-7 3-ethylpyridine 
• 271-63-6 7-Azaindole 
• 149489-03-2 tert-butyl (3-ethylpyridin-2-yl)carbamate 
• 844503-09-9 3-ethenyl-2-nitropyridine 
• 54231-32-2 3-chloro-2-nitropyridine 
• 1603-40-3 3-methylpyridin-2-ylamine 
• 138343-75-6 tert-butyl (3-methylpyridin-2-yl)carbamate 
• 13534-99-1 2-Amino-3-bromopyridine 
• 557-20-0 diethylzinc 
• 54230-88-5 8-bromotetrazolo[1,5-a]pyridine 
• 52200-48-3 3-bromo-2-chloropyridine 
• 110-86-1 pyridine 
• 14906-62-8 3-ethylpyridine N-oxide 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 906069-76-9 2-[1-(3-ethyl-pyridin-2-ylcarbamoyl)-cyclopentylmethyl]-pentanoic acid benzyl ester 
• 1037253-14-7 5-bromo-3-ethylpyridin-2-amine 
• 96440-05-0 2-chloro-3-ethylpyridine 

Relevant articles and documents

Mild, General, and Regioselective Synthesis of 2-Aminopyridines from Pyridine N -Oxides via N -(2-Pyridyl)pyridinium Salts

A synthesis of 2-aminopyridines from pyridine N-oxides via their corresponding N-(2-pyridyl)pyridinium salts has been demonstrated and investigated. The reaction sequence features a highly regioselective conversion of the N-oxide into its pyridinium salt

Iron-Catalyzed Amination of Strong Aliphatic C(sp3)-H Bonds

A concept for intramolecular denitrogenative C(sp3)-H amination of 1,2,3,4-tetrazoles bearing unactivated primary, secondary, and tertiary C-H bonds is discovered. This catalytic amination follows an unprecedented metalloradical activation mechanism. The utility of the method is showcased with the short synthesis of a bioactive molecule. Moreover, an initial effort has been embarked on for the enantioselective C(sp3)-H amination through the catalyst design. Collectively, this study underlines the development of C(sp3)-H bond functionalization chemistry that should find wide application in the context of drug discovery and natural product synthesis.

Rational Development of Remote C?H Functionalization of Biphenyl: Experimental and Computational Studies

A simple and efficient nitrile-directed meta-C?H olefination, acetoxylation, and iodination of biaryl compounds is reported. Compared to the previous approach of installing a complex U-shaped template to achieve a molecular U-turn and assemble the large-sized cyclophane transition state for the remote C?H activation, a synthetically useful phenyl nitrile functional group could also direct remote meta-C?H activation. This reaction provides a useful method for the modification of biaryl compounds because the nitrile group can be readily converted to amines, acids, amides, or other heterocycles. Notably, the remote meta-selectivity of biphenylnitriles could not be expected from previous results with a macrocyclophane nitrile template. DFT computational studies show that a ligand-containing Pd–Ag heterodimeric transition state (TS) favors the desired remote meta-selectivity. Control experiments demonstrate the directing effect of the nitrile group and exclude the possibility of non-directed meta-C?H activation. Substituted 2-pyridone ligands were found to be key in assisting the cleavage of the meta-C?H bond in the concerted metalation–deprotonation (CMD) process.

PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS

The present invention relates to a catalytic method for the conversion of amide-containing compouds by means of a build-in directing group and upon the action of a heteronucleophilic compound (in se an amine (RNH2 or RNHR') or an alcohol (ROH) or a thiol (RSH)) in the presence of a metal catalyst to respectively esters, thioesters, carbonates, thiocarbonates and to what is defined as amide-containing compounds (such as carboxamides, urea, carbamates, thiocarbamates). The present invention also relates to these amide-containing compounds having a build-in directing group (DG), as well as the use of such directing groups in the catalytic directed cleavage of N-DG amides with the use of heteronucleophiles (in se an amine (RNH2 or RNHR') or an alcohol (ROH) or thiol (RSH)).

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

Method for inhibition of HIV related viruses

Treatment of AIDS, inhibition of the replication of HIV and related viruses thereof, and formulations using thiourea derivative compounds or salts thereof is disclosed. Also disclosed are novel thiourea derivative compounds.